Nebulized hypertonic saline via positive expiratory pressure versus via jet nebulizer in patients with severe cystic fibrosis.

Hdl Handle:
http://hdl.handle.net/10147/138741
Title:
Nebulized hypertonic saline via positive expiratory pressure versus via jet nebulizer in patients with severe cystic fibrosis.
Authors:
O'Connell, Oisin J; O'Farrell, Carmel; Harrison, Mike J; Eustace, Joseph A; Henry, Michael T; Plant, Barry J
Affiliation:
Cork Adult Cystic Fibrosis Centre, Department of Respiratory Medicine, Cork University Hospital, University College Cork, Wilton, Cork, Ireland.
Citation:
Nebulized hypertonic saline via positive expiratory pressure versus via jet nebulizer in patients with severe cystic fibrosis. 2011, 56 (6):771-5 Respir Care
Journal:
Respiratory care
Issue Date:
Jun-2011
URI:
http://hdl.handle.net/10147/138741
DOI:
10.4187/respcare.00866
PubMed ID:
21333079
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/21333079
Abstract:
Nebulized hypertonic saline is a highly effective therapy for patients with cystic fibrosis (CF), yet 10% of patients are intolerant of hypertonic saline administered via jet nebulizer. Positive expiratory pressure (PEP) nebulizers splint open the airways and offers a more controlled rate of nebulization.; In 4 consecutive adult CF patients who were intolerant of hypertonic saline via jet nebulizer, we nebulized 6% hypertonic saline via a PEP nebulizer. We measured the number of days the patients required intravenous antibiotics from enrollment to study end, compared to an equal period before PEP, and the mean time between the patients' 3 most recent infective pulmonary exacerbation episodes before PEP to their next exacerbation after PEP. Patients also completed a Likert-scale adverse-effects questionnaire on hypertonic saline via PEP versus jet nebulizer.; The 4 patients had severe CF pulmonary disease and all fully tolerated hypertonic saline via PEP, for 77, 92, 128, and 137 days, respectively until the study end date. There were fewer days of antibiotics in 3 of the 4 patients, from 45 to 20 days, 66 to 14 days, and 28 to 0 days (mean relative risk reduction 53%, P = .11). The other patient had 63 days of antibiotics during both the PEP and the jet nebulizer periods. There was a mean 3.6-fold longer time to next infective pulmonary exacerbation during the PEP period (P = .07). Adverse effects were less with PEP: chest tightness 68% (P = .04), bad taste 62% (P = .06), cough 47% (P = .10), and sore throat 50% (P = .20).; Hypertonic saline via PEP nebulizer benefits CF patients who do not tolerate hypertonic saline via jet nebulizer.
Item Type:
Article
Language:
en
MeSH:
Administration, Inhalation; Adult; Albuterol; Anti-Bacterial Agents; Bronchodilator Agents; Cystic Fibrosis; Female; Humans; Nebulizers and Vaporizers; Questionnaires; Respiratory Function Tests; Saline Solution, Hypertonic; Treatment Outcome
ISSN:
0020-1324

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Connell, Oisin Jen
dc.contributor.authorO'Farrell, Carmelen
dc.contributor.authorHarrison, Mike Jen
dc.contributor.authorEustace, Joseph Aen
dc.contributor.authorHenry, Michael Ten
dc.contributor.authorPlant, Barry Jen
dc.date.accessioned2011-08-03T15:04:43Z-
dc.date.available2011-08-03T15:04:43Z-
dc.date.issued2011-06-
dc.identifier.citationNebulized hypertonic saline via positive expiratory pressure versus via jet nebulizer in patients with severe cystic fibrosis. 2011, 56 (6):771-5 Respir Careen
dc.identifier.issn0020-1324-
dc.identifier.pmid21333079-
dc.identifier.doi10.4187/respcare.00866-
dc.identifier.urihttp://hdl.handle.net/10147/138741-
dc.description.abstractNebulized hypertonic saline is a highly effective therapy for patients with cystic fibrosis (CF), yet 10% of patients are intolerant of hypertonic saline administered via jet nebulizer. Positive expiratory pressure (PEP) nebulizers splint open the airways and offers a more controlled rate of nebulization.-
dc.description.abstractIn 4 consecutive adult CF patients who were intolerant of hypertonic saline via jet nebulizer, we nebulized 6% hypertonic saline via a PEP nebulizer. We measured the number of days the patients required intravenous antibiotics from enrollment to study end, compared to an equal period before PEP, and the mean time between the patients' 3 most recent infective pulmonary exacerbation episodes before PEP to their next exacerbation after PEP. Patients also completed a Likert-scale adverse-effects questionnaire on hypertonic saline via PEP versus jet nebulizer.-
dc.description.abstractThe 4 patients had severe CF pulmonary disease and all fully tolerated hypertonic saline via PEP, for 77, 92, 128, and 137 days, respectively until the study end date. There were fewer days of antibiotics in 3 of the 4 patients, from 45 to 20 days, 66 to 14 days, and 28 to 0 days (mean relative risk reduction 53%, P = .11). The other patient had 63 days of antibiotics during both the PEP and the jet nebulizer periods. There was a mean 3.6-fold longer time to next infective pulmonary exacerbation during the PEP period (P = .07). Adverse effects were less with PEP: chest tightness 68% (P = .04), bad taste 62% (P = .06), cough 47% (P = .10), and sore throat 50% (P = .20).-
dc.description.abstractHypertonic saline via PEP nebulizer benefits CF patients who do not tolerate hypertonic saline via jet nebulizer.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21333079en
dc.subject.meshAdministration, Inhalation-
dc.subject.meshAdult-
dc.subject.meshAlbuterol-
dc.subject.meshAnti-Bacterial Agents-
dc.subject.meshBronchodilator Agents-
dc.subject.meshCystic Fibrosis-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshNebulizers and Vaporizers-
dc.subject.meshQuestionnaires-
dc.subject.meshRespiratory Function Tests-
dc.subject.meshSaline Solution, Hypertonic-
dc.subject.meshTreatment Outcome-
dc.titleNebulized hypertonic saline via positive expiratory pressure versus via jet nebulizer in patients with severe cystic fibrosis.en
dc.typeArticleen
dc.contributor.departmentCork Adult Cystic Fibrosis Centre, Department of Respiratory Medicine, Cork University Hospital, University College Cork, Wilton, Cork, Ireland.en
dc.identifier.journalRespiratory careen
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.